Literature DB >> 25364509

Liposomes as vaccine delivery systems: a review of the recent advances.

Reto A Schwendener1.   

Abstract

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

Entities:  

Keywords:  adjuvants; antigens; archaeosomes; liposomes; therapeutic cancer vaccines; vaccines; veterinary vaccines; virosomes

Year:  2014        PMID: 25364509      PMCID: PMC4212474          DOI: 10.1177/2051013614541440

Source DB:  PubMed          Journal:  Ther Adv Vaccines        ISSN: 2051-0136


  181 in total

Review 1.  Vaccine adjuvant formulations: a pharmaceutical perspective.

Authors:  Luis A Brito; Padma Malyala; Derek T O'Hagan
Journal:  Semin Immunol       Date:  2013-07-12       Impact factor: 11.130

2.  Liposomes as immunological adjuvants.

Authors:  A C Allison; G Gregoriadis
Journal:  Recent Results Cancer Res       Date:  1976

3.  The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.

Authors:  Takehisa Hebishima; Eiji Yuba; Kenji Kono; Shin-Nosuke Takeshima; Yoshihiro Ito; Yoko Aida
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

4.  Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.

Authors:  Rajesh Ravindran; Mithun Maji; Nahid Ali
Journal:  Mol Pharm       Date:  2011-12-14       Impact factor: 4.939

Review 5.  Archaeal lipid mucosal vaccine adjuvant and delivery system.

Authors:  Girishchandra B Patel; Wangxue Chen
Journal:  Expert Rev Vaccines       Date:  2010-04       Impact factor: 5.217

6.  Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.

Authors:  Malou Henriksen-Lacey; Dennis Christensen; Vincent W Bramwell; Thomas Lindenstrøm; Else Marie Agger; Peter Andersen; Yvonne Perrie
Journal:  Mol Pharm       Date:  2010-12-15       Impact factor: 4.939

7.  Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization.

Authors:  Prem N Gupta; Suresh P Vyas
Journal:  Colloids Surf B Biointerfaces       Date:  2010-08-26       Impact factor: 5.268

8.  Reduction of Salmonella enteritidis number after infections by immunization of liposome-associated recombinant SefA.

Authors:  Yue Pang; Yanlong Zhang; Huiguo Wang; Jinhua Jin; Jun Piao; Jingai Piao; Qingping Liu; Wenzhe Li
Journal:  Avian Dis       Date:  2013-09       Impact factor: 1.577

9.  Potential use of a liposome-encapsulated mixture of lipopolysaccharide core types (R1, R2, R3 and R4) of Escherichia coli in controlling colisepticaemia in chickens.

Authors:  D R Anuruddhika Dissanayake; Thula G Wijewardana; Gnana A Gunawardena; Ian R Poxton
Journal:  J Med Microbiol       Date:  2010-01       Impact factor: 2.472

10.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14
View more
  107 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

2.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

Review 3.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 4.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 5.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 6.  Liposomal systems as carriers for bioactive compounds.

Authors:  Ana Maria Sper Simão; Maytê Bolean; Thuanny Alexandra Campos Cury; Rodrigo Guerino Stabeli; Rosangela Itri; Pietro Ciancaglini
Journal:  Biophys Rev       Date:  2015-10-10

7.  Cationic Liposome-Oligonucleotide Complex as an Alternative Adjuvant for Polyclonal Antibody Production in New Zealand White Rabbits (Oryctolaguscuniculus).

Authors:  Erin S Lee; Clinton Sc Walker; Jacob E Moskowitz; Valerie A Johnson; Lon V Kendall
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

8.  From allergen to oral vaccine carrier: A new face of ragweed pollen.

Authors:  Md Jasim Uddin; Harvinder Singh Gill
Journal:  Int J Pharm       Date:  2018-05-03       Impact factor: 5.875

Review 9.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

Review 10.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.